B7-1/CD80 Antibody Summary
| Immunogen |
Peptide with sequence C-HLRVNQTFNWNTTK corresponding to internal region according to NP_005182.1.
|
| Epitope |
C-HLRVNQTFNWNTTK
|
| Clonality |
Polyclonal
|
| Host |
Goat
|
| Gene |
CD80
|
| Purity |
Immunogen affinity purified
|
| Innovators Reward |
Test in a species/application not listed above to receive a full credit towards a future purchase.
Learn about the Innovators Reward
|
Applications/Dilutions
| Dilutions |
|
|
| Application Notes |
WB: Approx. 60 kDa band observed in human lymph node and human tonsil lysates (calculated MW of 33.0 kDa band according to NP_005182.1). The observed molecular weight corresponds to earlier findings with different antibodies from other sources.
|
|
| Publications |
|
Packaging, Storage & Formulations
| Storage |
Store at -20C. Avoid freeze-thaw cycles.
|
| Buffer |
0.5 mg/ml Tris (pH 7.3) and 0.5% BSA
|
| Preservative |
0.02% Sodium Azide
|
| Concentration |
0.5 mg/ml
|
| Purity |
Immunogen affinity purified
|
Alternate Names for B7-1/CD80 Antibody
- Activation B7-1 antigen
- B7
- B71
- B7-1
- BB1
- CD28LG1
- CD28LGB7-1 antigen)
- CD80 antigen
- CD80 molecule
- CD80
- costimulatory factor CD80
- costimulatory molecule variant IgV-CD80
- CTLA-4 counter-receptor B7.1
- T-lymphocyte activation antigen CD80
Background
CD80 is a 60 kD highly glycosylated protein. It is a member of the Ig superfamily, also known as B7-1, B7 and Ly-53. CD80 is constitutively expressed on dendritic cells and monocytes/macrophages, and inducibly expressed on activated B and T cells. The ligation of CD28 on T cells with CD80 and CD86 (B7-2) on antigen presenting cells (such as dendritic cells, macrophages, and B cells) elicits co-stimulation of T cells resulting in enhanced cell activation, proliferation, and cytokine production. CD80 appears to be expressed later in the immune response than CD86. CD80 can also bind to CD152, also known as CTLA-4, to deliver an inhibitory signal to T cells. The 16-10A1 antibody has been shown to block the co-stimulation of T cells by activated B cells in vitro and to block the binding of CTLA-4 to CD80.
